arsonic acids - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	arsonic acids	go back to main search page
Accession:	CHEBI:50955	browse the term
Definition:	Arsonic acid and its As-hydrocarbyl derivatives.

show annotations for term's descendants Sort by:
Rat (636) Mouse (745) Human (653) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (636)

arsanilic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

brain-derived neurotrophic factor

decreases expression
multiple interactions

Arsanilic Acid results in decreased expression of BDNF mRNA; Arsanilic Acid results in decreased expression of BDNF protein
Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of BDNF protein]]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

caspase 3

increases activity
increases cleavage
multiple interactions
increases expression

Arsanilic Acid results in increased activity of CASP3 protein
Arsanilic Acid results in increased cleavage of CASP3 protein
Dexamethasone inhibits the reaction [Arsanilic Acid results in increased cleavage of CASP3 protein]; Dexamethasone inhibits the reaction [Arsanilic Acid results in increased expression of CASP3 mRNA]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in increased cleavage of CASP3 protein]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in increased expression of CASP3 mRNA]]

PMID:23848144 PMID:30628712

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity

Arsanilic Acid results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

neurotrophic receptor tyrosine kinase 2

decreases expression
multiple interactions

Arsanilic Acid results in decreased expression of NTRK2 mRNA; Arsanilic Acid results in decreased expression of NTRK2 protein
Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of NTRK2 protein]]

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

solute carrier family 12 member 5

decreases expression
multiple interactions

Arsanilic Acid results in decreased expression of SLC12A5 mRNA; Arsanilic Acid results in decreased expression of SLC12A5 protein
Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 mRNA]; Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 protein]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 mRNA]]; Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [Arsanilic Acid results in decreased expression of SLC12A5 protein]]

NCBI chr 3:153,696,517...153,735,801
Ensembl chr 3:153,696,517...153,735,765

methylarsonic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin-like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of A2ML1 mRNA

NCBI chr 4:161,815,111...161,857,286
Ensembl chr 4:161,814,708...161,857,343

G

acetoacetyl-CoA synthetase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AACS mRNA

NCBI chr12:31,113,098...31,156,411
Ensembl chr12:31,113,098...31,160,954

G

alanine and arginine rich domain containing protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AARD mRNA

NCBI chr 7:83,364,478...83,369,319
Ensembl chr 7:83,364,204...83,369,317

G

ATP binding cassette subfamily B member 1A

increases expression

monomethylarsonic acid results in increased expression of ABCB1A mRNA; monomethylarsonic acid results in increased expression of ABCB1A protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

increases expression
affects expression

monomethylarsonic acid results in increased expression of ABCC1 mRNA; monomethylarsonic acid results in increased expression of ABCC1 protein
monomethylarsonic acid affects the expression of ABCC1 mRNA

PMID:16436460 PMID:24091636

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

increases expression

monomethylarsonic acid results in increased expression of ABCC2 mRNA; monomethylarsonic acid results in increased expression of ABCC2 protein

PMID:16436460 PMID:24091636

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression

monomethylarsonic acid results in increased expression of ABCC3 mRNA; monomethylarsonic acid results in increased expression of ABCC3 protein

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ArfGAP with coiled-coil, ankyrin repeat and PH domains 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACAP1 mRNA

NCBI chr10:54,605,323...54,619,472
Ensembl chr10:54,605,323...54,619,472

G

acyl-CoA thioesterase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOT1 mRNA

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

acyl-CoA thioesterase 12

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOT12 mRNA

NCBI chr 2:22,986,867...23,027,538
Ensembl chr 2:22,986,626...23,027,536

G

acyl-CoA oxidase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ACOX2 mRNA

NCBI chr15:16,660,584...16,692,160
Ensembl chr15:16,660,272...16,692,160

G

acrosin binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ACRBP mRNA

NCBI chr 4:157,851,149...157,864,211
Ensembl chr 4:157,841,841...157,864,213

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADAMTS4 mRNA

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065

G

ADAM metallopeptidase with thrombospondin type 1 motif, 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADAMTS6 mRNA

NCBI chr 2:35,421,483...35,633,305
Ensembl chr 2:35,421,510...35,633,298

G

adhesion G protein-coupled receptor G1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADGRG1 mRNA

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

adrenomedullin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adrenoceptor alpha 2B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADRA2B mRNA

NCBI chr 3:114,585,174...114,589,220
Ensembl chr 3:114,585,169...114,589,355

G

adrenoceptor beta 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ADRB1 mRNA

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ADRB2 mRNA

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

ALF transcription elongation factor 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AFF3 mRNA

NCBI chr 9:40,399,099...40,856,716
Ensembl chr 9:40,404,375...40,857,247

G

alpha-fetoprotein

increases expression

monomethylarsonic acid results in increased expression of AFP mRNA

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

anterior gradient 3, protein disulphide isomerase family member

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AGR3 mRNA

NCBI chr 6:52,643,391...52,666,638
Ensembl chr 6:52,643,391...52,666,638

G

AT hook, DNA binding motif, containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AHDC1 mRNA

NCBI chr 5:145,228,228...145,294,170
Ensembl chr 5:145,228,227...145,294,145

G

aryl hydrocarbon receptor

multiple interactions

AHR mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of CYP1A1 protein]; monomethylarsonic acid results in decreased expression of and affects the localization of AHR protein

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

adenylate kinase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AK4 mRNA

NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618

G

aldo-keto reductase family 7, member A2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AKR7A5 mRNA

NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909

G

AKT serine/threonine kinase 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of AKT1 mRNA

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldolase, fructose-bisphosphate C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ALDOC mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

alpha-kinase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ALPK1 mRNA

NCBI chr 2:216,126,939...216,247,180
Ensembl chr 2:216,128,825...216,247,157

G

alkaline phosphatase, placental

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AKP3 mRNA

NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606

G

angiopoietin like 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANGPTL7 mRNA

NCBI chr 5:158,932,096...158,937,281
Ensembl chr 5:158,932,794...158,937,324

G

ankyrin repeat domain 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANKRD1 mRNA

NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919

G

ANKRD40 C-terminal like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANKRD40CL mRNA

NCBI chr10:79,227,791...79,236,365
Ensembl chr10:79,231,211...79,235,324

G

annexin A8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ANXA8 mRNA

NCBI chr16:9,397,144...9,412,072
Ensembl chr16:9,397,113...9,412,043

G

apolipoprotein L7a like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of APOL7A mRNA

NCBI chr 7:109,118,559...109,149,798
Ensembl chr 7:109,131,064...109,147,649

G

apolipoprotein L9a

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of APOL9A mRNA

NCBI chr 7:109,140,871...109,149,799
Ensembl chr 7:109,140,871...109,147,649

G

amphiregulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

Rho GTPase activating protein 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP15 mRNA

NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265

G

Rho GTPase activating protein 25

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP25 mRNA

NCBI chr 4:119,896,844...119,974,982
Ensembl chr 4:119,896,844...119,974,982

G

Rho GTPase activating protein 30

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP30 mRNA

NCBI chr13:83,822,290...83,843,634
Ensembl chr13:83,822,283...83,854,885

G

Rho GTPase activating protein 45

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP45 mRNA

NCBI chr 7:9,674,873...9,690,286
Ensembl chr 7:9,674,897...9,690,268

G

Rho GTPase activating protein 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGAP8 mRNA

NCBI chr 7:115,842,223...115,902,094
Ensembl chr 7:115,850,654...115,902,093

G

Rho GDP dissociation inhibitor beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARHGDIB mRNA

NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658

G

Rho guanine nucleotide exchange factor 38

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ARHGEF38 mRNA

NCBI chr 2:221,610,212...221,739,841
Ensembl chr 2:221,613,070...221,740,079

G

ARF like GTPase 5C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ARL5C mRNA

NCBI chr10:82,985,213...82,993,425
Ensembl chr10:82,985,216...82,992,002

G

ARF like GTPase 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ARL9 mRNA

NCBI chr14:31,157,573...31,166,803
Ensembl chr14:31,157,586...31,166,699

G

arsenite methyltransferase

increases metabolic processing
increases expression
multiple interactions
increases chemical synthesis

AS3MT protein polymorphism results in increased metabolism of monomethylarsonic acid; AS3MT protein results in increased metabolism of monomethylarsonic acid
monomethylarsonic acid results in increased expression of AS3MT protein
[AS3MT gene polymorphism affects the susceptibility to Arsenic] which results in increased abundance of monomethylarsonic acid; [AS3MT protein polymorphism results in increased metabolism of arsenite] which results in increased chemical synthesis of monomethylarsonic acid; [AS3MT protein polymorphism results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of Cacodylic Acid; [AS3MT protein polymorphism results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of dimethylarsinous acid; [AS3MT protein results in increased metabolism of arsenite] which results in increased chemical synthesis of monomethylarsonic acid; [AS3MT protein results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of Cacodylic Acid; [AS3MT protein results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of dimethylarsinous acid
AS3MT protein results in increased chemical synthesis of monomethylarsonic acid

PMID:22005461 PMID:22868225 PMID:24845704 PMID:36399430

NCBI chr 1:245,595,939...245,628,921
Ensembl chr 1:245,596,108...245,627,872

G

ankyrin repeat and SOCS box-containing 14

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASB14 mRNA

NCBI chr16:2,095,567...2,123,259
Ensembl chr16:2,095,644...2,115,135

G

ankyrin repeat and SOCS box-containing 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASB4 mRNA

NCBI chr 4:33,506,992...33,544,630
Ensembl chr 4:33,506,992...33,544,630

G

aspartic peptidase, retroviral-like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ASPRV1 mRNA

NCBI chr 4:119,077,415...119,078,887
Ensembl chr 4:119,077,356...119,078,379

G

activating transcription factor 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 7 interacting protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATF7IP2 mRNA

NCBI chr10:5,403,099...5,445,989
Ensembl chr10:5,403,105...5,446,142

G

ATPase phospholipid transporting 10D (putative)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATP10D mRNA

NCBI chr14:35,911,728...36,012,549
Ensembl chr14:35,912,141...36,012,564

G

ATPase copper transporting beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ATP7B mRNA

NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636

G

Beta-1,3-galactosyltransferase 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of B3GALT5 mRNA

NCBI chr11:35,584,273...35,630,922
Ensembl chr11:35,585,220...35,630,917

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of B3GNT5 mRNA

NCBI chr11:81,141,102...81,153,206
Ensembl chr11:81,140,599...81,156,166

G

B-cell scaffold protein with ankyrin repeats 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BANK1 mRNA

NCBI chr 2:224,530,475...224,800,420
Ensembl chr 2:224,530,475...224,800,405

G

Btg3 associated nuclear protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BANP mRNA

NCBI chr19:50,007,710...50,082,742
Ensembl chr19:50,007,881...50,082,738

G

BCL6 co-repressor-like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BCORL1 mRNA

NCBI chr X:127,516,504...127,584,529
Ensembl chr X:127,537,538...127,584,087

G

bifunctional apoptosis regulator

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BFAR mRNA

NCBI chr10:1,552,019...1,585,040
Ensembl chr10:1,552,072...1,585,038

G

basic helix-loop-helix family, member e41

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BHLHE41 mRNA

NCBI chr 4:178,834,264...178,838,618
Ensembl chr 4:178,834,271...178,838,468

G

BLK proto-oncogene, Src family tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BLK mRNA

NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031

G

basic helix-loop-helix ARNT like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of BMAL1 mRNA

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

Bri3 binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BRI3BP mRNA

NCBI chr12:31,176,742...31,188,563
Ensembl chr12:31,173,971...31,188,572

G

Bruton tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BTK mRNA

NCBI chr X:97,722,796...97,762,315
Ensembl chr X:97,722,802...97,761,853

G

B and T lymphocyte associated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of BTLA mRNA

NCBI chr11:55,563,683...55,588,187
Ensembl chr11:55,564,899...55,587,181

G

C1q and TNF related 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of C1QTNF3 mRNA

NCBI chr 2:59,917,099...59,939,519
Ensembl chr 2:59,917,188...59,939,433

G

similar to human chromosome 19 open reading frame 38

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of AB124611 mRNA

NCBI chr 8:20,061,494...20,095,705
Ensembl chr 8:20,078,639...20,095,696

G

calcium voltage-gated channel subunit alpha1 I

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CACNA1I mRNA

NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688

G

calcium/calmodulin-dependent protein kinase IG

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CAMK1G mRNA

NCBI chr13:104,877,909...104,901,658
Ensembl chr13:104,877,910...104,901,556

G

calpain 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CAPN3 mRNA

NCBI chr 3:107,407,518...107,457,858
Ensembl chr 3:107,407,850...107,457,858

G

caspase recruitment domain family, member 11

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CARD11 mRNA

NCBI chr12:13,621,140...13,758,115
Ensembl chr12:13,621,087...13,758,112

G

capping protein regulator and myosin 1 linker 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CARMIL2 mRNA

NCBI chr19:33,571,255...33,586,783
Ensembl chr19:33,574,257...33,586,965

G

caspase 3

affects response to substance
multiple interactions
increases expression

CASP3 protein affects the susceptibility to monomethylarsonic acid
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of CASP3 mRNA
monomethylarsonic acid results in increased expression of CASP3 mRNA
[monomethylarsonic acid co-treated with Buthionine Sulfoximine] results in increased activity of CASP3 protein

PMID:15963344 PMID:17481689 PMID:23192986

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

[CAT protein results in decreased oxidation of monomethylarsonous acid] which results in decreased chemical synthesis of monomethylarsonic acid

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cation channel, sperm associated 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CATSPER4 mRNA

NCBI chr 5:146,427,682...146,447,346
Ensembl chr 5:146,427,683...146,446,942

G

coiled-coil domain containing 122

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC122 mRNA

NCBI chr15:52,407,717...52,470,163
Ensembl chr15:52,407,717...52,470,163

G

coiled-coil domain containing 162

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC162 mRNA

NCBI chr20:45,044,891...45,237,905
Ensembl chr20:45,032,752...45,236,193

G

coiled-coil domain containing 71-like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CCDC71L mRNA

NCBI chr 6:48,960,020...48,964,112
Ensembl chr 6:48,960,191...48,960,841
Ensembl chr 6:48,960,191...48,960,841

G

coiled-coil domain containing 78

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC78 mRNA

NCBI chr10:14,808,355...14,812,284
Ensembl chr10:14,807,710...14,812,282

G

coiled-coil domain containing 87

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC87 mRNA

NCBI chr 1:202,135,021...202,137,717
Ensembl chr 1:202,134,963...202,138,337

G

coiled-coil domain containing 92B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCDC92B mRNA

NCBI chr10:59,479,798...59,501,486
Ensembl chr10:59,479,743...59,501,495

G

C-C motif chemokine ligand 22

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCL22 mRNA

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

cellular communication network factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cyclin D1

increases expression

monomethylarsonic acid results in increased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin E1

increases expression

monomethylarsonic acid results in increased expression of CCNE1 mRNA

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

C-C motif chemokine receptor 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCR6 mRNA

NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603

G

C-C motif chemokine receptor 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CCR7 mRNA

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

CD180 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD180 mRNA

NCBI chr 2:33,855,940...33,870,046
Ensembl chr 2:33,855,991...33,899,936

G

Cd2 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD2 mRNA

NCBI chr 2:188,710,895...188,724,044
Ensembl chr 2:188,710,900...188,724,026

G

CD22 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD22 mRNA

NCBI chr 1:86,116,376...86,132,782
Ensembl chr 1:86,117,459...86,132,322

G

Cd28 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD28 mRNA

NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685

G

CD37 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD37 mRNA

NCBI chr 1:95,719,171...95,724,662
Ensembl chr 1:95,719,190...95,724,648

G

CD40 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD40 mRNA

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

CD46 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD46 mRNA

NCBI chr13:106,575,586...106,606,325
Ensembl chr13:106,574,858...106,660,445

G

Cd5 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD5 mRNA

NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313

G

CD52 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD52 mRNA

NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348

G

Cd53 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD53 mRNA

NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657

G

Cd6 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD6 mRNA

NCBI chr 1:207,442,873...207,481,703
Ensembl chr 1:207,442,877...207,481,634

G

Cd69 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD69 mRNA

NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542

G

CD79a molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD79A mRNA

NCBI chr 1:80,493,581...80,497,936
Ensembl chr 1:80,493,581...80,497,935

G

CD79b molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD79B mRNA

NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625

G

CD83 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD83 mRNA

NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083

G

CD84 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD84 mRNA

NCBI chr13:84,327,580...84,367,153
Ensembl chr13:84,327,553...84,362,076

G

CD86 molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CD86 mRNA

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cell division cycle 25B

decreases activity

monomethylarsonic acid results in decreased activity of CDC25B protein

NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272

G

CDC42 effector protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CDC42EP2 mRNA

NCBI chr 1:203,202,000...203,210,891
Ensembl chr 1:203,201,873...203,210,897

G

cadherin 1

increases expression

monomethylarsonic acid results in increased expression of CDH1 mRNA

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

increases expression

monomethylarsonic acid results in increased expression of CDH2 mRNA

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cyclin dependent kinase like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CDKL1 mRNA

NCBI chr 6:88,224,154...88,273,434
Ensembl chr 6:88,224,143...88,270,276

G

cyclin-dependent kinase inhibitor 1A

decreases expression
multiple interactions

monomethylarsonic acid results in decreased expression of CDKN1A mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of CDKN1A mRNA

PMID:17481689 PMID:23192986

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CECR2, histone acetyl-lysine reader

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CECR2 mRNA

NCBI chr 4:153,890,310...153,998,078
Ensembl chr 4:153,890,206...153,993,451

G

carboxylesterase 2F

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CES2F mRNA

NCBI chr19:7,527...14,898
Ensembl chr19:7,527...14,898

G

cilia and flagella associated protein 47

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CFAP47 mRNA

NCBI chr X:43,264,687...43,616,607
Ensembl chr X:43,263,490...43,616,852

G

chondroadherin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHAD mRNA

NCBI chr10:79,512,170...79,515,941
Ensembl chr10:79,511,931...79,515,940

G

cysteine and histidine rich domain containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHORDC1 mRNA

NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162

G

cholinergic receptor nicotinic alpha 9 subunit

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CHRNA9 mRNA

NCBI chr14:42,235,218...42,241,939
Ensembl chr14:42,235,226...42,242,192

G

carbohydrate sulfotransferase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CHST3 mRNA

NCBI chr20:28,114,386...28,152,046
Ensembl chr20:28,114,404...28,121,807

G

circadian associated repressor of transcription

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIART mRNA

NCBI chr 2:183,419,819...183,424,845
Ensembl chr 2:183,419,819...183,423,313

G

class II, major histocompatibility complex, transactivator

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIITA mRNA

NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440

G

cartilage intermediate layer protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CILP mRNA

NCBI chr 8:65,777,281...65,792,251
Ensembl chr 8:65,777,281...65,792,251

G

cold inducible RNA binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CIRBP mRNA

NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818

G

cardiotrophin-like cytokine factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLCF1 mRNA

NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605

G

C-type lectin domain containing 7A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLEC7A mRNA

NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897

G

clusterin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CLU mRNA

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

cannabinoid receptor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CNR2 mRNA

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

cochlin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COCH mRNA

NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109

G

collagen type XI alpha 2 chain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of COL11A2 mRNA

NCBI chr20:4,786,932...4,816,598
Ensembl chr20:4,786,929...4,815,985

G

collagen type VII alpha 1 chain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of COL7A1 mRNA

NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252

G

collagen like tail subunit of asymmetric acetylcholinesterase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COLQ mRNA

NCBI chr16:6,731,850...6,824,973
Ensembl chr16:6,731,858...6,787,107

G

coronin 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CORO1A mRNA

NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534

G

coactosin-like F-actin binding protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of COTL1 mRNA

NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689

G

cleavage and polyadenylation specific factor 4-like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CPSF4L mRNA

NCBI chr10:98,741,816...98,756,069
Ensembl chr10:98,743,649...98,751,590

G

carboxypeptidase X (M14 family), member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CPXM1 mRNA

NCBI chr 3:117,588,532...117,595,330
Ensembl chr 3:117,588,532...117,595,330

G

complement C3d receptor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CR2 mRNA

NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235

G

CDP-L-ribitol pyrophosphorylase A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CRPPA mRNA

NCBI chr 6:53,120,264...53,397,030
Ensembl chr 6:53,121,438...53,397,028

G

cytotoxic and regulatory T cell molecule

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CRTAM mRNA

NCBI chr 8:41,340,117...41,377,381
Ensembl chr 8:41,340,837...41,377,343

G

cryptochrome circadian regulator 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CRY1 mRNA

NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091

G

cysteine and serine rich nuclear protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CSRNP2 mRNA

NCBI chr 7:131,594,232...131,610,075
Ensembl chr 7:131,594,232...131,610,075

G

catenin alpha 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CTNNA3 mRNA

NCBI chr20:23,614,469...25,200,026
Ensembl chr20:23,623,560...25,199,978

G

C-X-C motif chemokine ligand 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CXCL9 mRNA

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

cytochrome b-245 beta chain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CYBB mRNA

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

AHR mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of CYP1A1 protein]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of CYP1A1 protein]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; monomethylarsonic acid results in increased expression of and results in increased activity of CYP1A1 protein
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of CYP1A1 mRNA
monomethylarsonic acid results in increased expression of CYP1A1 mRNA

PMID:24161444 PMID:34876320

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

monomethylarsonic acid results in increased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily b, polypeptide 1

multiple interactions
increases expression

[monomethylarsonic acid co-treated with Diethylnitrosamine] results in increased expression of CYP2B1 mRNA; [monomethylarsonic acid co-treated with Diethylnitrosamine] results in increased expression of CYP2B1 protein
monomethylarsonic acid results in increased expression of CYP2B1 mRNA

PMID:12115560 PMID:17481689

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

multiple interactions

[monomethylarsonic acid co-treated with Diethylnitrosamine] results in increased expression of CYP2B2 mRNA

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, subfamily 2, polypeptide 11

increases expression

monomethylarsonic acid results in increased expression of CYP2C11 mRNA

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 4, subfamily f, polypeptide 18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of CYP4F18 mRNA

NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940

G

DAB adaptor protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DAB1 mRNA

NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552

G

D-box binding PAR bZIP transcription factor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DBP mRNA

NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745

G

doublecortin-like kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DCLK3 mRNA

NCBI chr 8:111,401,544...111,453,999
Ensembl chr 8:111,401,358...111,453,999

G

damage specific DNA binding protein 2

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of DDB2 mRNA

NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631

G

DEF6 guanine nucleotide exchange factor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DEF6 mRNA

NCBI chr20:6,268,579...6,290,030
Ensembl chr20:6,268,601...6,289,961

G

defensin alpha 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DEFA21 mRNA

NCBI chr16:70,342,530...70,344,854
Ensembl chr16:70,342,530...70,344,836

G

7-dehydrocholesterol reductase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

dehydrogenase/reductase 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DHRS9 mRNA

NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241

G

DIRAS family GTPase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DIRAS2 mRNA

NCBI chr17:12,730,040...12,761,511
Ensembl chr17:12,725,149...12,761,663

G

dynein, axonemal, heavy chain 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNAH10 mRNA

NCBI chr12:31,823,451...31,946,857
Ensembl chr12:31,822,733...32,007,069

G

dynein axonemal intermediate chain 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNAI4 mRNA

NCBI chr 5:117,787,398...117,876,216
Ensembl chr 5:117,788,464...117,876,127

G

DnaJ heat shock protein family (Hsp40) member B13

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNAJB13 mRNA

NCBI chr 1:154,848,586...154,863,042
Ensembl chr 1:154,848,594...154,862,963

G

DnaJ heat shock protein family (Hsp40) member B3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNAJB3 mRNA

NCBI chr 9:88,795,542...88,796,555
Ensembl chr 9:88,795,488...88,796,560

G

deoxyribonuclease 1 like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DNASE1L2 mRNA

NCBI chr10:13,471,850...13,473,447
Ensembl chr10:13,471,479...13,473,763

G

deoxyribonuclease 1L3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DNASE1L3 mRNA

NCBI chr15:16,922,335...16,948,322
Ensembl chr15:16,922,335...16,948,317

G

DNA methyltransferase 1

decreases expression

monomethylarsonic acid results in decreased expression of DNMT1 mRNA

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

dedicator of cytokinesis 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOCK10 mRNA

NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:81,843,604...82,101,525

G

dedicator of cytokinesis 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOCK2 mRNA

NCBI chr10:18,827,237...19,244,832
Ensembl chr10:18,827,239...19,244,808

G

docking protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DOK3 mRNA

NCBI chr17:9,109,633...9,115,188
Ensembl chr17:9,109,597...9,115,188

G

dopamine receptor D3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DRD3 mRNA

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

dual oxidase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOX2 mRNA

NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902

G

dual oxidase maturation factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOXA1 mRNA

NCBI chr 3:109,249,815...109,260,511
Ensembl chr 3:109,249,923...109,260,499

G

dual oxidase maturation factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUOXA2 mRNA

NCBI chr 3:109,245,337...109,249,055
Ensembl chr 3:109,245,476...109,248,968

G

dual specificity phosphatase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of DUSP2 mRNA

NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499

G

dual specificity phosphatase 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of DUSP6 mRNA

NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185

G

ELL associated factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EAF2 mRNA

NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610

G

endothelin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EDN1 mRNA

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

ephrin A3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EFNA3 mRNA

NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736

G

early growth response 1

increases expression
multiple interactions

monomethylarsonic acid results in increased expression of EGR1 mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of EGR1 mRNA

PMID:15345372 PMID:23192986

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EGR3 mRNA

NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627

G

extracellular leucine-rich repeat and fibronectin type III domain containing 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ELFN2 mRNA

NCBI chr 7:110,220,293...110,272,770
Ensembl chr 7:110,225,919...110,272,433

G

endonuclease, poly(U)-specific

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ENDOU mRNA

NCBI chr 7:128,844,872...128,866,572
Ensembl chr 7:128,844,862...128,866,596

G

eomesodermin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EOMES mRNA

NCBI chr 8:118,181,340...118,189,186
Ensembl chr 8:118,181,777...118,188,316

G

EPM2A glucan phosphatase, laforin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of EPM2A mRNA

NCBI chr 1:5,727,111...5,845,338
Ensembl chr 1:5,727,066...5,920,555

G

epiregulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

endogenous retrovirus group FRD member 1, envelope

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SYNA mRNA

NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264

G

estrogen receptor 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of ESR1 mRNA

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

ethanolamine kinase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ETNK2 mRNA

NCBI chr13:44,811,012...44,829,052
Ensembl chr13:44,811,015...44,829,037

G

ETS proto-oncogene 1, transcription factor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ETS1 mRNA

NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010

G

exophilin 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of EXPH5 mRNA

NCBI chr 8:53,698,825...53,775,371
Ensembl chr 8:53,698,852...53,773,169

G

fatty acid binding protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FABP1 mRNA

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FABP3 mRNA

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

family with sequence similarity 151, member A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FAM151A mRNA

NCBI chr 5:121,514,804...121,527,555
Ensembl chr 5:121,514,804...121,527,555

G

FAM161 centrosomal protein B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FAM161B mRNA

NCBI chr 6:103,990,603...104,007,754
Ensembl chr 6:103,992,170...104,018,776

G

family with sequence similarity 169, member B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FAM169B mRNA

NCBI chr 1:121,878,670...121,968,272
Ensembl chr 1:121,878,713...121,958,470

G

family with sequence similarity 89, member A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FAM89A mRNA

NCBI chr19:52,710,002...52,722,630
Ensembl chr19:52,710,019...52,722,631

G

FA complementation group D2

multiple interactions

[monomethylarsonic acid results in decreased activity of FANCD2 protein] which results in increased susceptibility to diepoxybutane; [monomethylarsonic acid results in decreased activity of FANCD2 protein] which results in increased susceptibility to Hydroxyurea; [monomethylarsonic acid results in decreased activity of FANCD2 protein] which results in increased susceptibility to Mitomycin

NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412

G

Fas cell surface death receptor

decreases expression

monomethylarsonic acid results in decreased expression of FAS mRNA

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

increases expression

monomethylarsonic acid results in increased expression of FASLG mRNA

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fructose-bisphosphatase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FBP1 mRNA

NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071

G

F-box and leucine-rich repeat protein 22

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FBXL22 mRNA

NCBI chr 8:67,069,998...67,076,685
Ensembl chr 8:67,069,998...67,076,685

G

F-box protein 24

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FBXO24 mRNA

NCBI chr12:19,072,668...19,083,067
Ensembl chr12:19,072,716...19,083,067

G

Fc epsilon receptor II

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCER2A mRNA

NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476

G

Fc receptor-like A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FCRLA mRNA

NCBI chr13:83,160,453...83,170,170
Ensembl chr13:83,160,398...83,170,762

G

farnesyl diphosphate farnesyl transferase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

fer-1-like family member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FER1L5 mRNA

NCBI chr 9:38,605,835...38,661,869
Ensembl chr 9:38,607,843...38,660,425

G

free fatty acid receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FFAR1 mRNA

NCBI chr 1:86,111,368...86,112,272
Ensembl chr 1:86,111,368...86,112,272

G

fibroblast growth factor 11

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FGF11 mRNA

NCBI chr10:54,516,508...54,522,067
Ensembl chr10:54,517,077...54,522,062

G

fibroblast growth factor 2

increases expression

monomethylarsonic acid results in increased expression of FGF2 mRNA

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor binding protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FGFBP3 mRNA

NCBI chr 1:234,644,023...234,646,028
Ensembl chr 1:234,644,019...234,646,547

G

FGR proto-oncogene, Src family tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FGR mRNA

NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326

G

FKBP prolyl isomerase 5

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of FKBP5 mRNA

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

flagellum associated containing coiled-coil domains 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLACC1 mRNA

NCBI chr 9:60,315,581...60,343,692
Ensembl chr 9:60,315,582...60,343,648

G

Fli-1 proto-oncogene, ETS transcription factor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLI1 mRNA

NCBI chr 8:30,831,422...30,950,468
Ensembl chr 8:30,832,753...30,950,433

G

filamin C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLNC mRNA

NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844

G

Fms related receptor tyrosine kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FLT3 mRNA

NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474

G

fibronectin type III domain containing 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FNDC10 mRNA

NCBI chr 5:166,299,587...166,311,477
Ensembl chr 5:166,300,122...166,310,326

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of FOS mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FOS mRNA

PMID:23192986 PMID:34876320

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

formyl peptide receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FPR1 mRNA

NCBI chr 1:58,745,019...58,756,776
Ensembl chr 1:58,747,246...58,756,559

G

fascin actin-bundling protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of FSCN1 mRNA

NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211

G

fucosyltransferase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of FUT1 mRNA

NCBI chr 1:96,086,934...96,090,352
Ensembl chr 1:96,086,635...96,090,616

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

guanylate binding protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GBP4 mRNA

NCBI chr 2:231,304,910...231,318,883
Ensembl chr 2:231,305,244...231,318,879

G

guanylate binding protein family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GBP9 mRNA

NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062
Ensembl chr14:4,730,453...4,839,062

G

GTP cyclohydrolase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GCH1 mRNA

NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698

G

germinal center-associated, signaling and motility

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GCSAM mRNA

NCBI chr11:55,195,757...55,207,011
Ensembl chr11:55,196,712...55,206,992

G

growth differentiation factor 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

GTPase, IMAP family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP6 mRNA

NCBI chr 4:77,653,703...77,659,112
Ensembl chr 4:77,652,610...77,659,116

G

GTPase, IMAP family member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GIMAP8 mRNA

NCBI chr 4:77,600,104...77,611,593
Ensembl chr 4:77,600,186...77,611,590

G

gap junction protein, beta 1

increases expression

monomethylarsonic acid results in increased expression of GJB1 mRNA

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

GLI family zinc finger 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GLI1 mRNA

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

glycine receptor, beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GLRB mRNA

NCBI chr 2:166,134,616...166,207,498
Ensembl chr 2:166,134,626...166,207,489

G

G protein subunit alpha 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GNA15 mRNA

NCBI chr 7:8,184,632...8,205,508
Ensembl chr 7:8,184,861...8,205,508

G

G protein subunit alpha transducin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GNAT1 mRNA

NCBI chr 8:108,350,935...108,355,671
Ensembl chr 8:108,350,935...108,355,671

G

G protein-coupled receptor 132

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR132 mRNA

NCBI chr 6:131,924,061...131,943,327
Ensembl chr 6:131,924,160...131,942,168

G

G protein-coupled receptor 157

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR157 mRNA

NCBI chr 5:160,550,703...160,566,432
Ensembl chr 5:160,550,713...160,566,432

G

G protein-coupled receptor 17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GPR17 mRNA

NCBI chr18:23,576,232...23,583,153
Ensembl chr18:23,577,242...23,582,966

G

G protein-coupled receptor 174

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR174 mRNA

NCBI chr X:72,355,452...72,396,146
Ensembl chr X:72,355,033...72,397,658

G

G protein-coupled receptor 179

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR179 mRNA

NCBI chr10:82,324,568...82,340,448
Ensembl chr10:82,337,771...82,340,448

G

G protein-coupled receptor 18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR18 mRNA

NCBI chr15:98,997,427...99,001,177
Ensembl chr15:98,997,259...99,001,470

G

G protein-coupled receptor 183

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR183 mRNA

NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559

G

G protein-coupled receptor 34

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GPR34 mRNA

NCBI chr X:9,104,829...9,113,796
Ensembl chr X:9,104,565...9,148,601

G

glutathione peroxidase 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GPX7 mRNA

NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:123,144,331...123,153,004

G

GRAM domain containing 2A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GRAMD2A mRNA

NCBI chr 8:60,079,744...60,117,788
Ensembl chr 8:60,080,338...60,115,842

G

GRB2-related adaptor protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GRAP mRNA

NCBI chr10:46,298,965...46,352,057
Ensembl chr10:46,332,909...46,352,056

G

glutathione S-transferase alpha 2

increases expression
decreases expression

monomethylarsonic acid results in increased expression of GSTA2 mRNA
monomethylarsonic acid results in decreased expression of GSTA2 mRNA; monomethylarsonic acid results in decreased expression of GSTA2 protein

PMID:15345372 PMID:16436460 PMID:17481689

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase mu 1

increases expression

monomethylarsonic acid results in increased expression of GSTM1 mRNA; monomethylarsonic acid results in increased expression of GSTM1 protein

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase omega 1

multiple interactions
increases reduction

[GSTO1 protein results in increased metabolism of monomethylarsonic acid] which results in increased chemical synthesis of monomethylarsonous acid
GSTO1 protein results in increased reduction of monomethylarsonic acid

PMID:12928150 PMID:15929903

NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468

G

glutathione S-transferase pi 1

increases expression

monomethylarsonic acid results in increased expression of GSTP1 mRNA

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

affects methylation
multiple interactions

GSTT1 protein affects the methylation of monomethylarsonic acid
[GSTT1 gene polymorphism affects the metabolism of Arsenic] which affects the abundance of monomethylarsonic acid

PMID:17431481 PMID:32650499

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

guanylate cyclase activator 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of GUCA1B mRNA

NCBI chr 9:13,599,619...13,607,455
Ensembl chr 9:13,599,619...13,607,455

G

granzyme A

decreases expression

monomethylarsonic acid results in decreased expression of GZMA mRNA

NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493

G

granzyme K

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of GZMK mRNA

NCBI chr 2:44,840,811...44,848,829
Ensembl chr 2:44,840,811...44,848,894

G

3-hydroxyanthranilate 3,4-dioxygenase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HAAO mRNA

NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877

G

hematopoietic cell specific Lyn substrate 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HCLS1 mRNA

NCBI chr11:63,817,482...63,840,943
Ensembl chr11:63,817,476...63,841,014

G

hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HCN2 mRNA

NCBI chr 7:9,969,801...9,988,839
Ensembl chr 7:9,970,368...9,988,841

G

histidine decarboxylase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HDC mRNA

NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341

G

hedgehog acyltransferase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HHAT mRNA

NCBI chr13:104,024,507...104,283,580
Ensembl chr13:104,010,916...104,282,893

G

hematopoietically expressed homeobox

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HHEX mRNA

NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042

G

hexokinase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HK2 mRNA

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

increases expression
multiple interactions
decreases expression

monomethylarsonic acid results in increased expression of HMOX1 mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of HMOX1 mRNA
monomethylarsonic acid results in decreased expression of HMOX1 mRNA

PMID:15345372 PMID:23192986 PMID:24091636

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

4-hydroxy-2-oxoglutarate aldolase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HOGA1 mRNA

NCBI chr 1:240,856,991...240,884,243
Ensembl chr 1:240,857,126...240,884,568

G

hippocalcin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HPCA mRNA

NCBI chr 5:141,455,616...141,466,252
Ensembl chr 5:141,455,613...141,463,841

G

heparan sulfate-glucosamine 3-sulfotransferase 3B1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HS3ST3B1 mRNA

NCBI chr10:48,561,473...48,593,970
Ensembl chr10:48,561,473...48,593,970

G

heat shock transcription factor 2 binding protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HSF2BP mRNA

NCBI chr20:10,035,562...10,123,059
Ensembl chr20:10,035,562...10,121,242

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA1A mRNA

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA1B mRNA

NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
Ensembl chr20:3,856,006...3,873,240

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family B (small) member 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HSPB7 mRNA

NCBI chr 5:153,727,782...153,731,268
Ensembl chr 5:153,727,588...153,731,266

G

heat shock protein family H (Hsp110) member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of HSPH1 mRNA

NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224

G

hydrogen voltage-gated channel 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of HVCN1 mRNA

NCBI chr12:34,341,673...34,370,010
Ensembl chr12:34,335,190...34,370,141

G

intercellular adhesion molecule 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ICAM1 mRNA

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

inducible T-cell co-stimulator

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ICOS mRNA

NCBI chr 9:62,368,075...62,406,900
Ensembl chr 9:62,383,832...62,405,672

G

insulin-like growth factor 1 receptor

increases expression

monomethylarsonic acid results in increased expression of IGF1R mRNA

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

insulin-like growth factor binding protein 1

increases expression

monomethylarsonic acid results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

immunoglobulin heavy chain like 16

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of IGHV4-1 mRNA

NCBI chr 6:134,212,480...134,234,464

G

immunoglobulin kappa variable like, pseudogene 13

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IGKV1-133 mRNA

NCBI chr 4:96,968,574...96,969,477

G

IKAROS family zinc finger 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IKZF1 mRNA

NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416

G

interleukin 10 receptor subunit alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL10RA mRNA

NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061

G

interleukin 13 receptor subunit alpha 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL13RA2 mRNA

NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381

G

interleukin 20 receptor subunit beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL20RB mRNA

NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942

G

interleukin 21 receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL21R mRNA

NCBI chr 1:180,168,028...180,195,690
Ensembl chr 1:180,168,097...180,195,522

G

interleukin 22 receptor subunit alpha 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL22RA2 mRNA

NCBI chr 1:14,353,736...14,377,844
Ensembl chr 1:14,364,489...14,377,844

G

interleukin 27 receptor subunit alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL27RA mRNA

NCBI chr19:24,109,963...24,121,977
Ensembl chr19:24,109,972...24,121,938

G

interleukin 36, beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL36B mRNA

NCBI chr 3:7,024,881...7,030,388
Ensembl chr 3:7,021,973...7,031,619

G

interleukin 5 receptor subunit alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL5RA mRNA

NCBI chr 4:139,630,652...139,664,593
Ensembl chr 4:139,632,066...139,668,544

G

interleukin 7 receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL7R mRNA

NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757

G

interleukin 9 receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IL9R mRNA

NCBI chr10:15,431,706...15,444,144
Ensembl chr10:15,431,706...15,441,990

G

insulin 1

multiple interactions

monomethylarsonic acid inhibits the reaction [INS1 protein results in increased uptake of Glucose]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin induced gene 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

interferon regulatory factor 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IRF4 mRNA

NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070

G

integrin subunit alpha 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ITGA10 mRNA

NCBI chr 2:184,182,869...184,202,172
Ensembl chr 2:184,182,869...184,202,172

G

integrin subunit alpha 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGA8 mRNA

NCBI chr17:75,304,004...75,501,510
Ensembl chr17:75,304,008...75,501,510

G

integrin subunit alpha L

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGAL mRNA

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

integrin subunit beta 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITGB8 mRNA

NCBI chr 6:140,125,002...140,208,261
Ensembl chr 6:140,127,203...140,208,476

G

inter-alpha trypsin inhibitor, heavy chain 3

increases expression

monomethylarsonic acid results in increased expression of ITIH3 mRNA

NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924

G

ITPRIP like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ITPRIPL2 mRNA

NCBI chr 1:172,801,152...172,803,047
Ensembl chr 1:172,796,849...172,802,950

G

IZUMO1 receptor, JUNO

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of IZUMO1R mRNA

NCBI chr 8:11,744,384...11,748,131
Ensembl chr 8:11,725,863...11,748,465

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel modifier subfamily G member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KCNG1 mRNA

NCBI chr 3:156,960,717...156,992,877
Ensembl chr 3:156,973,156...156,992,635

G

potassium voltage-gated channel interacting protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KCNIP4 mRNA

NCBI chr14:61,380,699...62,531,399
Ensembl chr14:61,381,076...62,530,144

G

potassium inwardly-rectifying channel, subfamily J, member 13

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNJ13 mRNA

NCBI chr 9:88,063,003...88,071,112
Ensembl chr 9:88,063,003...88,071,112

G

potassium two pore domain channel subfamily K member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of KCNK6 mRNA

NCBI chr 1:84,525,613...84,533,948
Ensembl chr 1:84,525,590...84,534,677

G

kelch-like family member 30

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLHL30 mRNA

NCBI chr 9:91,942,475...91,952,756
Ensembl chr 9:91,942,504...91,952,730

G

kelch-like family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLHL6 mRNA

NCBI chr11:80,970,917...81,010,593
Ensembl chr11:80,970,917...81,009,677

G

killer cell lectin like receptor B1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KLRB1 mRNA

NCBI chr 4:161,890,577...161,904,050
Ensembl chr 4:161,890,577...161,961,675

G

kynurenine 3-monooxygenase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KMO mRNA

NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881

G

keratin 12

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT12 mRNA

NCBI chr10:84,370,803...84,378,103
Ensembl chr10:84,370,883...84,378,045

G

keratin 17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT17 mRNA

NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392

G

keratin 18

decreases expression

monomethylarsonic acid results in decreased expression of KRT18 mRNA

NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
Ensembl chr10:133,157,475...133,161,166

G

keratin 27

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of KRT27 mRNA

NCBI chr10:84,298,684...84,303,967
Ensembl chr10:84,298,508...84,303,967

G

L3MBTL histone methyl-lysine binding protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of L3MBTL3 mRNA

NCBI chr 1:18,988,763...19,089,247
Ensembl chr 1:18,990,618...19,089,263

G

ladinin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LAD1 mRNA

NCBI chr13:47,249,605...47,263,967
Ensembl chr13:47,249,605...47,263,967

G

leucyl-tRNA synthetase 2, mitochondrial

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LARS2 mRNA

NCBI chr 8:123,010,271...123,106,395
Ensembl chr 8:123,010,293...123,106,395

G

lymphocyte transmembrane adaptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LAX1 mRNA

NCBI chr13:45,134,825...45,145,381
Ensembl chr13:45,134,834...45,145,381

G

lymphocyte cytosolic protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LCP1 mRNA

NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680

G

low density lipoprotein receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

lymphoid enhancer binding factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LEF1 mRNA

NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794

G

galectin 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LGALS2 mRNA

NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802

G

galectin 8

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of LGALS8 mRNA

NCBI chr17:58,024,652...58,052,764
Ensembl chr17:58,028,105...58,052,764

G

LHFPL tetraspan subfamily member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LHFPL2 mRNA

NCBI chr 2:25,281,771...25,428,128
Ensembl chr 2:25,281,901...25,427,950

G

lipase C, hepatic type

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LIPC mRNA

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lysophosphatidylcholine acyltransferase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LPCAT4 mRNA

NCBI chr 3:99,044,729...99,052,963
Ensembl chr 3:99,044,729...99,052,875

G

leupaxin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LPXN mRNA

NCBI chr 1:209,928,297...209,963,085
Ensembl chr 1:209,929,202...209,963,084

G

leucine rich repeat containing 31

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRC31 mRNA

NCBI chr 2:112,702,844...112,725,431
Ensembl chr 2:112,700,136...112,724,322

G

leucine-rich repeat kinase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LRRK2 mRNA

NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703

G

lanosterol synthase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

lymphotoxin alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTA mRNA

NCBI chr20:3,618,853...3,621,324
Ensembl chr20:3,618,853...3,620,859

G

lymphotoxin beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTB mRNA

NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381

G

leukotriene B4 receptor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LTB4R2 mRNA

NCBI chr15:29,258,712...29,260,531
Ensembl chr15:29,259,240...29,260,316

G

lymphocyte antigen 6 family member D

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LY6D mRNA

NCBI chr 7:106,643,225...106,644,733
Ensembl chr 7:106,643,232...106,644,733

G

lymphocyte antigen 6 family member G6C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of LY6G6C mRNA

NCBI chr20:3,753,632...3,757,205
Ensembl chr20:3,753,632...3,758,867

G

lymphocyte antigen 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LY9 mRNA

NCBI chr13:84,079,345...84,100,783
Ensembl chr13:84,079,458...84,100,823

G

LYL1, basic helix-loop-helix family member

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of LYL1 mRNA

NCBI chr19:23,452,140...23,455,007
Ensembl chr19:23,452,140...23,455,007

G

mitogen-activated protein kinase kinase kinase 19

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP3K19 mRNA

NCBI chr13:39,300,150...39,343,502
Ensembl chr13:39,300,163...39,343,767

G

mitogen-activated protein kinase kinase kinase 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP3K9 mRNA

NCBI chr 6:101,423,754...101,488,822
Ensembl chr 6:101,430,292...101,488,822

G

mitogen activated protein kinase kinase kinase kinase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MAP4K1 mRNA

NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493

G

mitogen activated protein kinase 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MAPK1 mRNA

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen-activated protein kinase 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MAPK15 mRNA

NCBI chr 7:107,694,907...107,714,640
Ensembl chr 7:107,694,964...107,714,645

G

melanin-concentrating hormone receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MCHR1 mRNA

NCBI chr 7:112,761,554...112,764,746
Ensembl chr 7:112,761,554...112,764,032

G

MDM2 proto-oncogene

increases expression
multiple interactions

monomethylarsonic acid results in increased expression of MDM2 mRNA
[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MDM2 mRNA

PMID:17481689 PMID:23192986

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

myocyte enhancer factor 2C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MEF2C mRNA

NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880

G

meiosis specific with coiled-coil domain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MEIOC mRNA

NCBI chr10:87,628,807...87,646,485
Ensembl chr10:87,628,875...87,646,752

G

milk fat globule EGF and factor V/VIII domain containing

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MFGE8 mRNA

NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073

G

major facilitator superfamily domain containing 12

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MFSD12 mRNA

NCBI chr 7:8,345,171...8,354,050
Ensembl chr 7:8,347,314...8,353,988

G

MFSD2 lysolipid transporter B, sphingolipid

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MFSD2B mRNA

NCBI chr 6:27,870,182...27,883,768
Ensembl chr 6:27,870,518...27,882,159

G

microRNA 145

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MIR145A mRNA

NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727

G

Mir155 host gene

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MIR155HG mRNA

NCBI chr11:23,773,468...23,775,697

G

microRNA 192

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MIR192 mRNA

NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055

G

mohawk homeobox

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MKX mRNA

NCBI chr17:55,077,073...55,156,877
Ensembl chr17:55,077,540...55,156,124

G

maestro heat-like repeat family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MROH6 mRNA

NCBI chr 7:107,566,212...107,576,469
Ensembl chr 7:107,569,554...107,574,173

G

maestro heat-like repeat family member 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MROH7 mRNA

NCBI chr 5:121,463,826...121,509,233
Ensembl chr 5:121,463,827...121,503,755

G

membrane spanning 4-domains A1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MS4A1 mRNA

NCBI chr 1:207,906,370...207,927,028
Ensembl chr 1:207,906,374...207,918,512

G

membrane spanning 4-domains A18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MS4A18 mRNA

NCBI chr 1:207,644,858...207,662,471
Ensembl chr 1:207,645,780...207,665,793

G

mutS homolog 2

decreases expression

monomethylarsonic acid results in decreased expression of MSH2 mRNA

NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938

G

misato mitochondrial distribution and morphology regulator 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MSTO1 mRNA

NCBI chr 2:174,305,945...174,310,230
Ensembl chr 2:174,301,861...174,310,216

G

metallothionein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MT1 mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

metallothionein 1, pseudogene 3

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MT1E mRNA

NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135

G

metallothionein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MT4 mRNA

NCBI chr19:10,863,813...10,865,909
Ensembl chr19:10,863,813...10,865,909

G

mevalonate diphosphate decarboxylase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MVD mRNA

NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971

G

mevalonate kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MVK mRNA

NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882

G

MX dynamin like GTPase 1

multiple interactions

[Arsenic results in increased abundance of monomethylarsonic acid] which affects the expression of MX1 mRNA
[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MX1 mRNA

PMID:28793237 PMID:34876320

NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507

G

Max dimerization protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MXD3 mRNA

NCBI chr17:9,301,430...9,305,156
Ensembl chr17:9,301,399...9,305,157

G

MYB proto-oncogene like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYBL1 mRNA

NCBI chr 5:9,582,905...9,618,179
Ensembl chr 5:9,582,934...9,618,183

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin IG

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MYO1G mRNA

NCBI chr14:81,386,701...81,401,843
Ensembl chr14:81,386,701...81,401,843

G

myotilin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of MYOT mRNA

NCBI chr18:36,705,244...36,724,849
Ensembl chr18:36,705,314...36,724,841

G

marginal zone B and B1 cell-specific protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of MZB1 mRNA

NCBI chr18:27,238,999...27,241,060
Ensembl chr18:27,239,001...27,241,094

G

N-6 adenine-specific DNA methyltransferase 1

increases abundance

N6AMT1 gene polymorphism results in increased abundance of monomethylarsonic acid

NCBI chr11:26,584,750...26,597,790
Ensembl chr11:26,584,724...26,608,248

G

N-acetylated alpha-linked acidic dipeptidase-like 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NAALADL1 mRNA

NCBI chr 1:203,400,632...203,414,195
Ensembl chr 1:203,400,631...203,414,195

G

napsin A aspartic peptidase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NAPSA mRNA

NCBI chr 1:95,064,726...95,077,101
Ensembl chr 1:95,064,900...95,077,094

G

neutrophil cytosolic factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NCF1 mRNA

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

noncompact myelin associated protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NCMAP mRNA

NCBI chr 5:147,608,042...147,623,266
Ensembl chr 5:147,610,677...147,618,775

G

N-myc downstream regulated 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NDRG1 mRNA

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

N-deacetylase and N-sulfotransferase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NDST3 mRNA

NCBI chr 2:211,702,728...211,868,159
Ensembl chr 2:211,704,898...211,854,584

G

nuclear paraspeckle assembly transcript 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NEAT1 mRNA

NCBI chr 1:203,129,229...203,140,014

G

nebulin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NEB mRNA

NCBI chr 3:36,613,677...36,811,618
Ensembl chr 3:36,613,716...36,811,574

G

nectin cell adhesion molecule 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NECTIN1 mRNA

NCBI chr 8:44,101,776...44,164,863
Ensembl chr 8:44,101,776...44,189,787

G

NFE2 like bZIP transcription factor 1

multiple interactions

[NFE2L1 protein alternative form results in decreased methylation of arsenite] which results in decreased abundance of monomethylarsonic acid

NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318

G

NFE2 like bZIP transcription factor 2

decreases expression
multiple interactions

monomethylarsonic acid results in decreased expression of NFE2L2 mRNA
monomethylarsonic acid results in increased expression of and affects the localization of NFE2L2 protein; NFE2L2 mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of NQO1 protein]

PMID:24091636 PMID:24161444

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor, interleukin 3 regulated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

nuclear factor kappa B subunit 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of NFKB1 mRNA

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

niban apoptosis regulator 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NIBAN3 mRNA

NCBI chr16:18,307,122...18,318,589
Ensembl chr16:18,307,221...18,318,585

G

NIPA-like domain containing 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NIPAL4 mRNA

NCBI chr10:30,583,926...30,600,640
Ensembl chr10:30,583,926...30,600,640

G

NLR family, pyrin domain containing 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NLRP9B mRNA

NCBI chr 1:68,291,180...68,341,512
Ensembl chr 1:68,291,180...68,341,512

G

neuromedin U

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NMU mRNA

NCBI chr14:31,844,564...31,872,196
Ensembl chr14:31,844,728...31,872,192

G

nocturnin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NOCT mRNA

NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400

G

Nodal modulator 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NOMO1 mRNA

NCBI chr 1:96,505,460...96,556,280
Ensembl chr 1:96,505,484...96,556,279

G

neuronal PAS domain protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NPAS4 mRNA

NCBI chr 1:202,281,260...202,298,681
Ensembl chr 1:202,281,958...202,286,724

G

neuropeptide FF receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NPFFR1 mRNA

NCBI chr20:29,539,795...29,573,951
Ensembl chr20:29,539,795...29,571,196

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

monomethylarsonic acid promotes the reaction [sulforaphane results in increased expression of and results in increased activity of NQO1 protein]; monomethylarsonic acid promotes the reaction [sulforaphane results in increased expression of NQO1 mRNA]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]; monomethylarsonic acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]; monomethylarsonic acid results in increased expression of and results in increased activity of NQO1 protein; NFE2L2 mutant form inhibits the reaction [monomethylarsonic acid results in increased expression of NQO1 protein]
monomethylarsonic acid results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

5' nucleotidase, ecto

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NT5E mRNA

NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881

G

nuclear GTPase, germinal center associated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NUGGC mRNA

NCBI chr15:39,821,851...39,866,122
Ensembl chr15:39,821,855...39,866,122

G

neurexophilin and PC-esterase domain family, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NXPE3 mRNA

NCBI chr11:44,726,905...44,777,694
Ensembl chr11:44,727,069...44,777,694

G

neurexophilin and PC-esterase domain family member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of NXPE4 mRNA

NCBI chr 8:48,502,697...48,744,101
Ensembl chr 8:48,722,440...48,744,100

G

nyctalopin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of NYX mRNA

NCBI chr X:9,280,864...9,301,900
Ensembl chr X:9,280,864...9,301,900

G

2'-5' oligoadenylate synthetase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of OAS2 mRNA

NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371

G

8-oxoguanine DNA glycosylase

increases expression

monomethylarsonic acid results in increased expression of OGG1 mRNA

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

olfactory receptor family 10 subfamily J member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of OR10J2 mRNA

NCBI chr13:85,723,300...85,724,290
Ensembl chr13:85,719,234...85,724,767

G

odd-skipped related transciption factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of OSR2 mRNA

NCBI chr 7:66,487,841...66,495,003
Ensembl chr 7:66,487,839...66,495,224

G

3-oxoacid CoA transferase 2A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of OXCT2A mRNA

NCBI chr 5:135,600,812...135,602,570
Ensembl chr 5:135,591,507...135,602,569

G

P2Y receptor family member 10

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of P2RY10 mRNA

NCBI chr X:72,121,558...72,207,174
Ensembl chr X:72,111,264...72,212,265

G

prolyl 4-hydroxylase subunit alpha 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of P4HA1 mRNA

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

parvin, gamma

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PARVG mRNA

NCBI chr 7:115,456,183...115,475,707
Ensembl chr 7:115,456,209...115,475,104

G

paired box 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PAX5 mRNA

NCBI chr 5:58,763,334...58,945,719
Ensembl chr 5:58,765,036...58,944,326

G

paired box 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PAX6 mRNA

NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014

G

phosphatidylethanolamine binding protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PBP2 mRNA

NCBI chr 4:168,155,827...168,157,121
Ensembl chr 4:168,155,709...168,157,117

G

protocadherin related 15

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCDH15 mRNA

NCBI chr20:13,997,094...15,496,446
Ensembl chr20:13,963,565...15,494,719

G

protocadherin gamma subfamily B, 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCDHGB1 mRNA

NCBI chr18:29,501,739...29,508,024

G

PC-esterase domain containing 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCED1B mRNA

NCBI chr 7:128,394,388...128,528,231
Ensembl chr 7:128,391,319...128,528,231

G

proliferating cell nuclear antigen

increases expression

monomethylarsonic acid results in increased expression of PCNA mRNA

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

proprotein convertase subtilisin/kexin type 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PCSK9 mRNA

NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688

G

pleckstrin homology-like domain, family A, member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PHLDA1 mRNA

NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861

G

paired-like homeodomain 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PITX1 mRNA

NCBI chr17:8,794,134...8,800,292
Ensembl chr17:8,794,134...8,800,291

G

phospholipase A2 group IIA

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLA2G2A mRNA

NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014

G

phospholipase A2, group IID

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLA2G2D mRNA

NCBI chr 5:151,016,010...151,022,531
Ensembl chr 5:151,018,870...151,022,525

G

phospholipase A2, group IVF

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLA2G4F mRNA

NCBI chr 3:107,249,053...107,266,201
Ensembl chr 3:107,250,075...107,264,689

G

plasminogen activator, urokinase receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLAUR mRNA

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595

G

phospholipase B1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLB1 mRNA

NCBI chr 6:24,087,051...24,227,167
Ensembl chr 6:24,089,214...24,210,117

G

phospholipase D family, member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLD4 mRNA

NCBI chr 6:131,818,860...131,827,457
Ensembl chr 6:131,818,860...131,826,376

G

pleckstrin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLEK mRNA

NCBI chr14:91,397,015...91,429,693
Ensembl chr14:91,397,019...91,454,131

G

pleckstrin homology and RhoGEF domain containing G4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLEKHG4 mRNA

NCBI chr19:33,251,788...33,266,490
Ensembl chr19:33,249,706...33,266,357

G

placenta expressed transcript 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLET1 mRNA

NCBI chr 8:50,842,242...50,853,666
Ensembl chr 8:50,841,854...50,853,659

G

polo-like kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PLK3 mRNA

NCBI chr 5:130,607,142...130,612,317
Ensembl chr 5:130,607,142...130,612,317

G

plexin C1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PLXNC1 mRNA

NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:29,390,048...29,543,779

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PMAIP1 mRNA

NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429

G

patatin-like phospholipase domain containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PNPLA1 mRNA

NCBI chr20:6,917,993...6,952,157
Ensembl chr20:6,917,931...6,952,375

G

patatin-like phospholipase domain containing 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PNPLA3 mRNA

NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077

G

POU class 2 homeobox associating factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of POU2AF1 mRNA

NCBI chr 8:51,521,813...51,548,819
Ensembl chr 8:51,474,015...51,548,819

G

POU class 2 homeobox 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of POU2F2 mRNA

NCBI chr 1:80,682,330...80,769,756
Ensembl chr 1:80,685,741...80,724,261

G

protein phosphatase 1, regulatory subunit 16B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PPP1R16B mRNA

NCBI chr 3:147,323,652...147,419,658
Ensembl chr 3:147,324,126...147,418,937

G

PRAME like 34

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PRAMEL34 mRNA

NCBI chr14:13,850,057...13,852,806
Ensembl chr14:13,850,057...13,852,806

G

protein kinase C, alpha

increases expression

monomethylarsonic acid results in increased expression of PRKCA mRNA

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

proline rich 5 like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PRR5L mRNA

NCBI chr 3:88,001,951...88,173,532
Ensembl chr 3:88,003,617...88,082,763

G

serine protease 16

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of PRSS16 mRNA

NCBI chr17:42,514,306...42,521,885
Ensembl chr17:42,514,306...42,521,884

G

phosphatase and tensin homolog

decreases expression

monomethylarsonic acid results in decreased expression of PTEN mRNA

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin F receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTGFR mRNA

NCBI chr 2:240,731,185...240,766,674
Ensembl chr 2:240,733,375...240,765,650

G

protein tyrosine phosphatase, non-receptor type 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPN7 mRNA

NCBI chr13:46,570,904...46,584,048
Ensembl chr13:46,571,712...46,583,308

G

protein tyrosine phosphatase, receptor type, C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPRC mRNA

NCBI chr13:49,596,193...49,708,283
Ensembl chr13:49,596,193...49,708,692

G

protein tyrosine phosphatase, receptor type, C-associated protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of PTPRCAP mRNA

NCBI chr 1:201,449,133...201,451,293
Ensembl chr 1:201,449,113...201,451,288

G

pyroglutamylated RFamide peptide receptor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of QRFPR mRNA

NCBI chr 2:119,053,083...119,096,864
Ensembl chr 2:119,053,511...119,096,792

G

RAB33A, member RAS oncogene family

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RAB33A mRNA

NCBI chr X:127,694,219...127,706,378
Ensembl chr X:127,694,964...127,706,378

G

RAD51 paralog C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RAD51C mRNA

NCBI chr10:72,205,032...72,231,643
Ensembl chr10:72,205,032...72,231,248

G

RPA1 related single stranded DNA binding protein, X-linked

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RADX mRNA

NCBI chr X:103,089,284...103,176,840
Ensembl chr X:103,089,284...103,176,838

G

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RAF1 mRNA

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

ral guanine nucleotide dissociation stimulator like 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RGL3 mRNA

NCBI chr 8:20,500,846...20,520,471
Ensembl chr 8:20,500,846...20,520,471

G

RAS protein activator like 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASAL3 mRNA

NCBI chr 7:11,396,554...11,411,347
Ensembl chr 7:11,396,090...11,411,465

G

ras related dexamethasone induced 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASD1 mRNA

NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186

G

RAS guanyl releasing protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RASGRP3 mRNA

NCBI chr 6:19,895,361...19,993,945
Ensembl chr 6:19,895,390...19,958,578

G

RAS-like family 11 member A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RASL11A mRNA

NCBI chr12:8,258,148...8,260,909
Ensembl chr12:8,258,159...8,262,576

G

REC114 meiotic recombination protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of REC114 mRNA

NCBI chr 8:59,063,352...59,221,439
Ensembl chr 8:59,063,352...59,149,887

G

REC8 meiotic recombination protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of REC8 mRNA

NCBI chr15:29,109,862...29,117,327
Ensembl chr15:29,109,863...29,117,326

G

receptor accessory protein 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REEP6 mRNA

NCBI chr 7:9,373,927...9,380,845
Ensembl chr 7:9,373,927...9,380,597

G

regenerating family member 3 beta

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REG3B mRNA

NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015

G

regenerating family member 3 gamma

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of REG3G mRNA

NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RELA mRNA

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RELT-like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RELL2 mRNA

NCBI chr18:29,789,996...29,793,986
Ensembl chr18:29,790,415...29,793,986

G

regulator of G-protein signaling 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RGS1 mRNA

NCBI chr13:56,018,546...56,022,889
Ensembl chr13:56,018,554...56,022,984

G

ras homolog family member H

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RHOH mRNA

NCBI chr14:42,341,135...42,371,971
Ensembl chr14:42,337,751...42,386,369

G

receptor-interacting serine-threonine kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RIPK3 mRNA

NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121

G

RHO family interacting cell polarization regulator 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RIPOR2 mRNA

NCBI chr17:40,323,748...40,547,482
Ensembl chr17:40,323,867...40,548,092

G

ribonuclease A family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RNASE6 mRNA

NCBI chr15:24,354,305...24,357,289
Ensembl chr15:24,354,303...24,357,328

G

ring finger protein 225

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RNF225 mRNA

NCBI chr 1:73,543,598...73,546,269
Ensembl chr 1:73,543,598...73,546,269

G

ring finger protein 24

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RNF24 mRNA

NCBI chr 3:118,520,459...118,575,213
Ensembl chr 3:118,525,349...118,541,080

G

ROS proto-oncogene 1 , receptor tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ROS1 mRNA

NCBI chr20:31,432,636...31,583,998
Ensembl chr20:31,432,637...31,583,865

G

ribonuclease P RNA component H1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of RPPH1 mRNA

NCBI chr15:24,033,679...24,033,935
Ensembl chr15:24,033,662...24,033,959

G

ribosomal protein S6 kinase related

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of RSKR mRNA

NCBI chr10:63,185,286...63,191,963
Ensembl chr10:63,156,044...63,191,141

G

RT1 class II, locus DOa

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of H2-OA mRNA

NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577

G

RT1 class II, locus DOb

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of H2-OB mRNA

NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667

G

rubicon like autophagy enhancer

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RUBCNL mRNA

NCBI chr15:50,332,458...50,377,494
Ensembl chr15:50,332,418...50,400,849

G

ryanodine receptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RYR1 mRNA

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812

G

ryanodine receptor 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of RYR3 mRNA

NCBI chr 3:99,431,755...99,979,125
Ensembl chr 3:99,432,505...99,704,961

G

S100 calcium binding protein G

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of S100G mRNA

NCBI chr X:31,705,853...31,708,422
Ensembl chr X:31,705,866...31,708,433

G

sphingosine-1-phosphate receptor 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of S1PR4 mRNA

NCBI chr 7:8,207,767...8,210,043
Ensembl chr 7:8,208,098...8,211,893

G

sacsin molecular chaperone

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SACS mRNA

NCBI chr15:35,285,783...35,370,335
Ensembl chr15:35,285,782...35,370,335

G

sterile alpha motif domain containing 4A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SAMD4 mRNA

NCBI chr15:20,135,994...20,352,131
Ensembl chr15:20,134,377...20,348,380

G

SAM domain, SH3 domain and nuclear localization signals, 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SAMSN1 mRNA

NCBI chr11:14,484,523...14,534,900
Ensembl chr11:14,483,893...14,534,900

G

SAM and SH3 domain containing 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SASH3 mRNA

NCBI chr X:127,326,815...127,341,521
Ensembl chr X:127,326,859...127,341,519

G

sciellin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SCEL mRNA

NCBI chr15:80,339,661...80,456,546
Ensembl chr15:80,339,951...80,456,372

G

sodium voltage-gated channel alpha subunit 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SCN4A mRNA

NCBI chr10:91,246,936...91,296,670
Ensembl chr10:91,246,936...91,296,545

G

secreted and transmembrane 1B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SECTM1A mRNA

NCBI chr10:106,324,070...106,333,779
Ensembl chr10:106,325,203...106,333,769

G

selectin L

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SELL mRNA

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

semaphorin 7A (John Milton Hagen blood group)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SEMA7A mRNA

NCBI chr 8:58,348,448...58,370,536
Ensembl chr 8:58,348,448...58,370,536

G

serpin family C member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SERPINC1 mRNA

NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293

G

serpin family F member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SERPINF2 mRNA

NCBI chr10:60,272,400...60,280,506
Ensembl chr10:60,272,400...60,281,243

G

secreted frizzled-related protein 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SFRP4 mRNA

NCBI chr17:45,278,867...45,330,806
Ensembl chr17:45,234,097...45,330,736

G

serum/glucocorticoid regulated kinase 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SGK1 mRNA

NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283

G

SH3 domain containing 21

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SH3D21 mRNA

NCBI chr 5:138,429,180...138,444,540
Ensembl chr 5:138,429,180...138,444,407

G

shroom family member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SHROOM4 mRNA

NCBI chr X:15,869,065...16,076,850
Ensembl chr X:15,869,065...16,076,869

G

signaling lymphocytic activation molecule family member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLAMF1 mRNA

NCBI chr13:84,270,316...84,305,497
Ensembl chr13:84,270,316...84,305,497

G

SLAM family member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLAMF6 mRNA

NCBI chr13:84,384,561...84,405,300
Ensembl chr13:84,383,742...84,405,300

G

SLAM family member 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLAMF7 mRNA

NCBI chr13:84,135,656...84,154,528
Ensembl chr13:84,136,899...84,154,105

G

solute carrier family 10 member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 10 member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC10A6 mRNA

NCBI chr14:6,080,716...6,102,902
Ensembl chr14:6,080,717...6,103,037

G

solute carrier family 13 member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC13A1 mRNA

NCBI chr 4:52,569,179...52,647,126
Ensembl chr 4:52,569,375...52,647,099

G

solute carrier family 14 member 1 (Kidd blood group)

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC14A1 mRNA

NCBI chr18:71,565,453...71,608,807
Ensembl chr18:71,565,454...71,595,146

G

solute carrier family 15, member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC15A5 mRNA

NCBI chr 4:170,878,021...170,971,620
Ensembl chr 4:170,878,021...170,971,620

G

solute carrier family 16 member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC16A8 mRNA

NCBI chr 7:110,818,274...110,822,069
Ensembl chr 7:110,818,274...110,822,069

G

solute carrier family 26 member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC26A2 mRNA

NCBI chr18:54,648,276...54,666,627
Ensembl chr18:54,652,951...54,666,626

G

solute carrier family 27 member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC27A3 mRNA

NCBI chr 2:175,853,241...175,857,909
Ensembl chr 2:175,853,241...175,857,909

G

solute carrier family 28 member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC28A2 mRNA

NCBI chr 3:109,324,815...109,387,702
Ensembl chr 3:109,366,996...109,387,702

G

solute carrier family 28 member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC28A3 mRNA

NCBI chr17:6,062,563...6,112,965
Ensembl chr17:6,062,549...6,114,038

G

solute carrier family 29 member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC29A4 mRNA

NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834

G

solute carrier family 2 member 1

increases import

SLC2A1 protein results in increased import of monomethylarsonic acid

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

solute carrier family 2 member 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC2A5 mRNA

NCBI chr 5:160,583,055...160,609,994
Ensembl chr 5:160,583,234...160,611,106

G

solute carrier family 34 member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC34A2 mRNA

NCBI chr14:57,910,931...57,930,236
Ensembl chr14:57,910,480...57,930,436

G

solute carrier family 38, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC38A3 mRNA

NCBI chr 8:108,323,889...108,339,959
Ensembl chr 8:108,323,894...108,339,988

G

solute carrier family 38, member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC38A8 mRNA

NCBI chr19:47,522,781...47,561,443
Ensembl chr19:47,525,301...47,554,726

G

solute carrier family 39 member 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC39A2 mRNA

NCBI chr15:24,590,738...24,592,850
Ensembl chr15:24,590,738...24,592,850

G

solute carrier family 41, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC41A3 mRNA

NCBI chr 4:123,109,555...123,154,766
Ensembl chr 4:123,112,748...123,154,766

G

solute carrier family 5 member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC5A3 mRNA

NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883

G

solute carrier family 5 member 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC5A9 mRNA

NCBI chr 5:126,709,762...126,733,468
Ensembl chr 5:126,709,769...126,733,468

G

solute carrier family 6 member 18

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC6A18 mRNA

NCBI chr 1:29,607,288...29,621,925
Ensembl chr 1:29,608,077...29,621,925

G

solute carrier family 7 member 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC7A9 mRNA

NCBI chr 1:88,109,517...88,132,653
Ensembl chr 1:88,110,644...88,132,641

G

solute carrier family 8 member A3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLC8A3 mRNA

NCBI chr 6:100,874,359...101,007,989
Ensembl chr 6:100,874,369...101,007,508

G

solute carrier family 9 member A3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SLC9A3 mRNA

NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:29,124,674...29,167,417

G

solute carrier organic anion transporter family, member 5A1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SLCO5A1 mRNA

NCBI chr 5:6,228,938...6,358,124
Ensembl chr 5:6,228,973...6,352,913

G

stannin

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SNN mRNA

NCBI chr10:4,572,933...4,581,606
Ensembl chr10:4,572,376...4,584,021
Ensembl chr 1:4,572,376...4,584,021

G

sterol O-acyltransferase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SOAT2 mRNA

NCBI chr 7:133,281,818...133,294,915
Ensembl chr 7:133,281,818...133,294,915

G

superoxide dismutase 1

increases expression

monomethylarsonic acid results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

increases expression

monomethylarsonic acid results in increased expression of SOD2 mRNA

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

SP100 nuclear antigen

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SP140 mRNA

NCBI chr 9:86,310,990...86,377,036
Ensembl chr 9:86,311,032...86,377,034

G

sperm associated antigen 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPAG1 mRNA

NCBI chr 7:67,361,474...67,421,369
Ensembl chr 7:67,361,477...67,421,368

G

spermatogenesis associated 6-like

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SPATA6L mRNA

NCBI chr 1:226,630,470...226,682,979
Ensembl chr 1:226,641,518...226,682,884

G

spermatogenesis associated, serine-rich 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPATS1 mRNA

NCBI chr 9:15,527,179...15,562,286
Ensembl chr 9:15,527,142...15,562,280

G

small proline-rich protein 1A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRR1A mRNA

NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063

G

small proline rich protein 2A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRR2H mRNA

NCBI chr 2:177,815,964...177,816,236
Ensembl chr 2:177,815,964...177,816,236

G

sprouty RTK signaling antagonist 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPRY4 mRNA

NCBI chr18:30,436,513...30,451,426
Ensembl chr18:30,436,443...30,453,004

G

serine palmitoyltransferase, small subunit B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SPTSSB mRNA

NCBI chr 2:154,133,728...154,162,127
Ensembl chr 2:154,133,733...154,163,120

G

squalene epoxidase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SQLE mRNA

NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of SRC mRNA

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

sterol regulatory element binding transcription factor 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SREBF2 mRNA

NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848

G

SRSF protein kinase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SRPK3 mRNA

NCBI chr X:151,510,452...151,515,208
Ensembl chr X:151,510,539...151,515,198

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST3GAL4 mRNA

NCBI chr 8:33,415,666...33,465,319
Ensembl chr 8:33,415,671...33,524,389

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST6GALNAC3 mRNA

NCBI chr 2:242,129,755...242,645,120
Ensembl chr 2:242,129,763...242,645,133

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST8SIA4 mRNA

NCBI chr 9:95,990,131...96,084,661
Ensembl chr 9:95,993,503...96,084,653

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ST8SIA6 mRNA

NCBI chr17:76,740,755...76,884,178
Ensembl chr17:76,745,224...76,884,299

G

signal transducing adaptor family member 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of STAP1 mRNA

NCBI chr14:21,950,466...21,981,395
Ensembl chr14:21,952,496...21,981,245

G

signal transducer and activator of transcription 3

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of STAT3 mRNA

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

sushi domain containing 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SUSD3 mRNA

NCBI chr17:15,400,845...15,417,851
Ensembl chr17:15,400,845...15,417,044

G

synaptonemal complex protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SYCP2 mRNA

NCBI chr 3:165,431,715...165,502,134
Ensembl chr 3:165,436,331...165,498,789

G

synaptotagmin 5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of SYT5 mRNA

NCBI chr 1:69,277,351...69,285,071
Ensembl chr 1:69,277,351...69,285,067

G

synaptotagmin 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of SYT8 mRNA

NCBI chr 1:197,588,126...197,593,598
Ensembl chr 1:197,590,149...197,593,504

G

TBC1 domain family, member 10C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TBC1D10C mRNA

NCBI chr 1:201,476,258...201,484,876
Ensembl chr 1:201,477,157...201,564,920

G

transcription factor 23

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TCF23 mRNA

NCBI chr 6:25,397,889...25,406,639
Ensembl chr 6:25,397,937...25,405,880

G

transcription factor 24

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TCF24 mRNA

NCBI chr 5:9,274,659...9,282,876
Ensembl chr 5:9,227,131...9,279,636

G

t-complex protein 10b

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TCP10A mRNA

NCBI chr 1:52,937,823...52,961,307
Ensembl chr 1:52,937,917...52,961,307

G

terminal nucleotidyltransferase 5B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TENT5B mRNA

NCBI chr 5:145,695,358...145,702,668
Ensembl chr 5:145,695,362...145,706,073
Ensembl chr11:145,695,362...145,706,073

G

transforming growth factor, beta 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

transforming growth factor, beta receptor 2

increases expression

monomethylarsonic acid results in increased expression of TGFBR2 mRNA

NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228

G

transglutaminase 7

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TGM7 mRNA

NCBI chr 3:108,051,890...108,068,116
Ensembl chr 3:108,051,890...108,076,239

G

thrombomodulin

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of THBD mRNA

NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193

G

thymocyte selection associated

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of THEMIS mRNA

NCBI chr 1:16,433,906...16,623,889
Ensembl chr 1:16,432,631...16,664,329

G

TRAF-interacting protein with forkhead-associated domain

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TIFA mRNA

NCBI chr 2:216,257,926...216,267,635
Ensembl chr 2:216,234,774...216,267,841

G

toll-like receptor 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TLR8 mRNA

NCBI chr X:27,091,780...27,116,092
Ensembl chr X:27,091,778...27,116,549

G

toll-like receptor 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TLR9 mRNA

NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796

G

transmembrane 4 L six family member 20

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TM4SF20 mRNA

NCBI chr 9:84,038,715...84,052,615
Ensembl chr 9:84,038,715...84,052,615

G

transmembrane p24 trafficking protein 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TMED6 mRNA

NCBI chr19:34,966,813...34,972,900
Ensembl chr19:34,966,813...34,972,900

G

transmembrane protein 140

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TMEM140 mRNA

NCBI chr 4:63,536,477...63,547,478
Ensembl chr 4:63,536,168...63,548,455

G

transmembrane protein 156

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM156 mRNA

NCBI chr14:43,221,464...43,252,453
Ensembl chr14:43,223,381...43,252,449

G

transmembrane protein 17

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM17 mRNA

NCBI chr14:96,483,648...96,524,238
Ensembl chr14:96,518,793...96,524,233

G

transmembrane protein 266

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM266 mRNA

NCBI chr 8:55,707,122...55,820,692
Ensembl chr 8:55,707,122...55,820,692

G

transmembrane protein 71

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TMEM71 mRNA

NCBI chr 7:98,276,975...98,323,161
Ensembl chr 7:98,276,975...98,315,858

G

TNF receptor superfamily member 13B

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFRSF13B mRNA

NCBI chr10:45,801,860...45,824,932
Ensembl chr10:45,801,860...45,822,987

G

TNF receptor superfamily member 13C

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFRSF13C mRNA

NCBI chr 7:113,736,046...113,738,523
Ensembl chr 7:113,736,055...113,738,517

G

TNF receptor superfamily member 1A

decreases expression

monomethylarsonic acid results in decreased expression of TNFRSF1A mRNA

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

TNF receptor superfamily member 25

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TNFRSF25 mRNA

NCBI chr 5:162,621,669...162,626,341
Ensembl chr 5:162,622,075...162,626,341

G

TNF superfamily member 11

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFSF11 mRNA

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

TNF superfamily member 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNFSF8 mRNA

NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421

G

troponin I2, fast skeletal type

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNNI2 mRNA

NCBI chr 1:197,595,012...197,597,554
Ensembl chr 1:197,594,813...197,597,560

G

troponin T3, fast skeletal type

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TNNT3 mRNA

NCBI chr 1:197,652,535...197,669,736
Ensembl chr 1:197,652,431...197,669,535

G

tumor protein p53

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tubulin polymerization promoting protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TPPP mRNA

NCBI chr 1:29,257,111...29,281,134
Ensembl chr 1:29,261,255...29,281,134

G

transformer 2 alpha

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TRA2A mRNA

NCBI chr 4:78,220,838...78,239,737
Ensembl chr 4:78,220,883...78,239,712

G

TNF receptor-associated factor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRAF1 mRNA

NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807

G

Tnf receptor-associated factor 3

decreases expression

monomethylarsonic acid results in decreased expression of TRAF3 mRNA

NCBI chr 6:130,199,696...130,307,168
Ensembl chr 6:130,206,484...130,305,481

G

TRAF3 interacting protein 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRAF3IP3 mRNA

NCBI chr13:104,694,802...104,719,655
Ensembl chr13:104,694,805...104,719,673

G

tetratricopeptide repeat and ankyrin repeat containing 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRANK1 mRNA

NCBI chr 8:111,275,973...111,355,491
Ensembl chr 8:111,276,354...111,355,092

G

T cell receptor associated transmembrane adaptor 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TRAT1 mRNA

NCBI chr11:52,035,750...52,077,805
Ensembl chr11:52,035,750...52,077,805

G

tripartite motif containing 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TRIM6 mRNA

NCBI chr 1:158,683,746...158,696,936
Ensembl chr 1:158,683,746...158,696,914

G

transient receptor potential cation channel, subfamily C, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRPC3 mRNA

NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855

G

transient receptor potential cation channel, subfamily V, member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRPV3 mRNA

NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296

G

transient receptor potential cation channel, subfamily V, member 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TRPV6 mRNA

NCBI chr 4:70,507,347...70,523,013
Ensembl chr 4:70,507,348...70,523,017

G

tetraspanin 32

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TSPAN32 mRNA

NCBI chr 1:198,190,128...198,204,447
Ensembl chr 1:198,190,164...198,204,445

G

tubulin tyrosine ligase like 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTLL2 mRNA

NCBI chr 1:52,967,183...52,976,690
Ensembl chr 1:52,968,408...52,976,697

G

tubulin tyrosine ligase like 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of TTLL3 mRNA

NCBI chr 4:146,532,958...146,558,425
Ensembl chr 4:146,533,953...146,557,889

G

tubulin tyrosine ligase like 9

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TTLL9 mRNA

NCBI chr 3:141,429,351...141,475,965
Ensembl chr 3:141,429,444...141,475,865

G

tweety family member 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TTYH3 mRNA

NCBI chr12:13,996,831...14,025,457
Ensembl chr12:13,997,045...14,025,459

G

TXK tyrosine kinase

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of TXK mRNA

NCBI chr14:35,463,369...35,519,448
Ensembl chr14:35,463,944...35,519,448

G

thioredoxin 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TXN mRNA

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thioredoxin reductase 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

uncoupling protein 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of UCP2 mRNA

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

UDP glucuronosyltransferase 1 family, polypeptide A2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of UGT1A2 mRNA

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A5

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of UGT1A5 mRNA

NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UL16 binding protein 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ULBP1 mRNA

NCBI chr 1:1,694,255...1,716,160

G

vascular cell adhesion molecule 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of VCAM1 mRNA

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

G

vascular endothelial growth factor A

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vanin 1

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of VNN1 mRNA

NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395

G

V-set pre-B cell surrogate light chain 3

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of VPREB3 mRNA

NCBI chr20:12,717,421...12,718,785
Ensembl chr20:12,716,779...12,719,520

G

vacuolar protein sorting 25 homolog

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of VPS25 mRNA

NCBI chr10:86,196,062...86,201,606
Ensembl chr10:86,188,812...86,231,829

G

WASP actin nucleation promoting factor

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of WAS mRNA

NCBI chr X:14,405,105...14,413,850
Ensembl chr X:14,405,124...14,413,849

G

WDFY family member 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of WDFY4 mRNA

NCBI chr16:8,221,853...8,450,494
Ensembl chr16:8,221,719...8,450,491

G

WD repeat domain 31

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of WDR31 mRNA

NCBI chr 5:75,897,074...75,917,461
Ensembl chr 5:75,898,353...75,917,417

G

WD repeat domain 54

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of WDR54 mRNA

NCBI chr 4:115,654,968...115,677,979
Ensembl chr 4:115,654,968...115,661,562

G

Wnt family member 1

multiple interactions

[sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] affects the expression of WNT1 mRNA

NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651

G

XK related 8

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of XKR8 mRNA

NCBI chr 5:144,938,061...144,945,195
Ensembl chr 5:144,938,064...144,945,195

G

X-prolyl aminopeptidase 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of XPNPEP2 mRNA

NCBI chr X:127,287,765...127,317,036
Ensembl chr X:127,287,979...127,317,223

G

zeta chain of T cell receptor associated protein kinase 70

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZAP70 mRNA

NCBI chr 9:38,989,750...39,011,701
Ensembl chr 9:38,989,750...39,011,700

G

zinc finger and BTB domain containing 16

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZBTB16 mRNA

NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011

G

zinc finger and BTB domain containing 40

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZBTB40 mRNA

NCBI chr 5:149,216,496...149,283,746
Ensembl chr 5:149,219,677...149,254,415

G

zinc finger CCCH type containing 6

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZC3H6 mRNA

NCBI chr 3:116,203,466...116,254,186
Ensembl chr 3:116,204,197...116,253,282

G

zinc finger DHHC-type palmitoyltransferase 19

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZDHHC19 mRNA

NCBI chr11:68,277,847...68,289,110
Ensembl chr11:68,277,848...68,288,954

G

zinc finger homeobox 2

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZFHX2 mRNA

NCBI chr15:28,533,155...28,565,667
Ensembl chr15:28,533,156...28,565,128

G

zinc finger protein 503

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP503 mRNA

NCBI chr15:2,313,060...2,316,848
Ensembl chr15:2,313,060...2,316,848

G

zinc finger protein 831

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP831 mRNA

NCBI chr 3:163,393,787...163,510,654
Ensembl chr 3:163,438,006...163,509,095

G

ZFP92 zinc finger protein

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZFP92 mRNA

NCBI chr X:151,116,794...151,142,451
Ensembl chr X:151,117,102...151,143,177

G

zinc finger protein 950

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in decreased expression of ZFP950 mRNA

NCBI chr 1:260,248,231...260,265,211
Ensembl chr 1:260,236,599...260,265,254

G

zinc finger, matrin type 4

multiple interactions

[sodium arsenate co-treated with sodium arsenite co-treated with monomethylarsonic acid co-treated with Cacodylic Acid] results in increased expression of ZMAT4 mRNA

NCBI chr16:67,969,410...68,361,377
Ensembl chr16:67,969,416...68,361,202

phenylarsonic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glutaminase

decreases expression
decreases activity

benzenearsonic acid results in decreased expression of GLS protein
benzenearsonic acid results in decreased activity of GLS protein

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

heme oxygenase 1

increases expression

benzenearsonic acid results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

roxarsone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiopoietin 1

decreases expression

Roxarsone results in decreased expression of ANGPT1 mRNA

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067

G

chondromodulin

decreases expression

Roxarsone results in decreased expression of CNMD mRNA

NCBI chr15:55,041,548...55,066,297
Ensembl chr15:55,041,561...55,066,297

G

C-X-C motif chemokine ligand 9

decreases expression

Roxarsone results in decreased expression of CXCL9 mRNA

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

ectonucleotide pyrophosphatase/phosphodiesterase 2

increases secretion

Roxarsone results in increased secretion of ENPP2 protein

NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827

G

FH2 domain containing 1

decreases expression

Roxarsone results in decreased expression of INF1 mRNA

NCBI chr 2:169,790,917...169,829,580
Ensembl chr 2:169,790,947...169,827,896

G

hepatocyte growth factor

increases expression

Roxarsone results in increased expression of HGF mRNA

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

leptin

decreases expression

Roxarsone results in decreased expression of LEP mRNA

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

matrix metallopeptidase 9

increases expression

Roxarsone results in increased expression of MMP9 mRNA; Roxarsone results in increased expression of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

increases expression
multiple interactions

Roxarsone results in increased expression of MTOR mRNA
Roxarsone results in increased expression of and results in increased phosphorylation of MTOR protein; Sirolimus inhibits the reaction [Roxarsone results in increased expression of and results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

nitric oxide synthase 3

multiple interactions

Roxarsone results in increased phosphorylation of and results in increased activity of NOS3 protein

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

platelet and endothelial cell adhesion molecule 1

increases expression
multiple interactions

Roxarsone results in increased expression of PECAM1 protein
Semaxinib inhibits the reaction [Roxarsone results in increased expression of PECAM1 protein]

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

plasminogen

decreases expression

Roxarsone results in decreased expression of PLG mRNA

NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786

G

ribosomal protein S6 kinase B1

multiple interactions
increases expression

Roxarsone results in increased expression of and results in increased phosphorylation of RPS6KB1 protein; Sirolimus inhibits the reaction [Roxarsone results in increased expression of and results in increased phosphorylation of RPS6KB1 protein]
Roxarsone results in increased expression of RPS6KB1 mRNA

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

vascular endothelial growth factor A

multiple interactions

Roxarsone results in increased expression of and results in increased secretion of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19874
chemical entity	19872
atom	19872
metalloid atom	15394
arsenic atom	14685
arsenic molecular entity	14685
arsenic oxoacid	4240
arsonic acids	636
arsonic acid +	636
methylarsonic acid	619
phenylarsonic acid +	16
Path 2
Term	Annotations
CHEBI ontology	19874
subatomic particle	19872
composite particle	19872
hadron	19872
baryon	19872
nucleon	19872
atomic nucleus	19872
atom	19872
main group element atom	19811
p-block element atom	19811
chalcogen	19563
oxygen atom	19535
oxygen molecular entity	19535
hydroxides	19341
oxoacid	18777
pnictogen oxoacid	14974
arsenic oxoacid	4240
arsonic acids	636
arsonic acid +	636
methylarsonic acid	619
phenylarsonic acid +	16

paths to the root